DAB389IL-2 (Denileukin Diftitox, ONTAK): Review of Clinical Trials to Date

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  Kuzel, Timothy M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

DAB389IL 2; HIV infection; Lymphoma; Pharmacokinetics; Psoriasis; Rheumatoid arthritis

Indexed keywords

DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2;

CLINICAL TRIAL; COMPARATIVE STUDY; CUTANEOUS T CELL LYMPHOMA; HUMAN; REVIEW; SKIN TUMOR;

CLINICAL TRIALS; DIPHTHERIA TOXIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INTERLEUKIN-2; LYMPHOMA, T-CELL, CUTANEOUS; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS;

EID: 0002442403     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.006     Document Type: Article

References (8)

1. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79:2547-2554.
2. Hesketh P, Caguioa P, Koh H, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993; 11:1682-1690.
3. 486IL-2 in hematological cancers. Cancer Res 1993; 53:3930-3934.
4. 486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk lymphoma 1993; 11:369-377.
5. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84:1765-1774.
6. 389IL-I) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91:399-405.
7. 389IL-2 for the treatment of mycosis fungoides. Blood 1997; 90 (suppl 1):586a (Abstract #2607).
8. 389IL-2) for the treatment of cutaneous T-cell lymphoma. Blood 1997; 90(suppl 1):326a (Abstract #1457).